EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Predictors of response to emergent therapies in paediatric immune thrombocytopenia

Candelaria O'Farrell iD, Taylor M Luckie, Matthew J Willis, Susan E Kirk, Brandon R Lucari, Michael E Scheurer, Xiaotian Gao, Amanda B Grimes

British Journal of Haematology · 2025

DOI: 10.1111/bjh.70064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Candelaria O'Farrell und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Immunoglobulins, Intravenous. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emergent therapies (ET), which include intravenous immunoglobulin (IVIG), corticosteroids and intravenous anti‐Rho(D) immunoglobulin, are used to treat acute episodes of bleeding in children with immune thrombocytopenia (ITP). There are currently no known biomarkers or clinical features predictive of treatment response to any specific ET. Thus, the treatment of ITP remains largely trial and error, exposing patients to potentially ineffective medications, which are often expensive and associated with adverse effects. We therefore sought to identify the predictors of treatment response through comparison of clinical characteristics in paediatric patients with ITP responsive to ET versus those non‐responsive to ET. We identified high rates of non‐response to ET in our cohort of 511 children diagnosed with ITP over a recent 5‐year period. Through a multivariable logistic regression model, we identified the presence of secondary ITP, the presence of systemic lupus erythematosus, a positive baseline direct antiglobulin test (DAT) and a high baseline IgA level as predictors of non‐response to IVIG. In the future, management guidelines that incorporate predictors of response could help individualize treatment for each patient, achieving better response rates that ensure less bleeding‐related morbidity and avoid unnecessary side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicImmunoglobulins, IntravenousHumansChildMaleFemaleChild, PreschoolAdolescentInfantTreatment OutcomeAdrenal Cortex HormonesRetrospective StudiesRho(D) Immune Globulin

Stichwörter der Autor:innen

ITPIVIGimmunohaematologypaediatric haematologypaediatricsplatelet disorders

Substanzen

Immunoglobulins, IntravenousAdrenal Cortex HormonesRho(D) Immune Globulin

Autor:innen und Institutionen

  • Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
  • Texas Children's Cancer and Hematology Center, Houston, Texas, USA.
  • Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.

ORCID-Profile: Candelaria O'Farrell

Zitieren

APA

O'Farrell, C., Luckie, T. M., Willis, M. J., Kirk, S. E., Lucari, B. R., Scheurer, M. E., Gao, X., & Grimes, A. B. (2025). Predictors of response to emergent therapies in paediatric immune thrombocytopenia. British Journal of Haematology. https://doi.org/10.1111/bjh.70064

Vancouver

O'Farrell C, Luckie TM, Willis MJ, Kirk SE, Lucari BR, Scheurer ME, et al. Predictors of response to emergent therapies in paediatric immune thrombocytopenia. British Journal of Haematology. 2025. doi:10.1111/bjh.70064

BibTeX
@article{OFarrell2025,
  author = {O'Farrell, Candelaria and Luckie, Taylor M and Willis, Matthew J and Kirk, Susan E and Lucari, Brandon R and Scheurer, Michael E and Gao, Xiaotian and Grimes, Amanda B},
  title = {Predictors of response to emergent therapies in paediatric immune thrombocytopenia},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.70064}
}
Kostenlos starten →